Literature DB >> 2913302

Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.

T Yoshioka1, T Fujita, T Kanai, Y Aizawa, T Kurumada, K Hasegawa, H Horikoshi.   

Abstract

A series of hindered phenols were investigated as hypolipidemic and/or hypoglycemic agents with ability to inhibit lipid peroxidation. 1,3-Benzoxathioles (9 and 22), phenoxypentanoic acid (34), phenoxypentanol (35a), phenoxynonanol (35b), phenylchloropropionic acid having a chromanyl group (25), and a thiazolidine compound (27) derived from 25, all having a hindered phenol group, were prepared and examined. Compound 27 showed the expected biological properties in vivo and in vitro without any liver weight increase. Biological activities of the analogous thiazolidine compounds, 43-58, were compared. Thus, (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]- benzyl]-2,4-thiazolidinedione (27) (CS-045) was found to have all of our expected properties and was selected as a candidate for further development as a hypoglycemic and hypolipidemic agent.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2913302     DOI: 10.1021/jm00122a022

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.

Authors:  Liting Deng; Benjamin L Cornett; Ken Mackie; Andrea G Hohmann
Journal:  Mol Pharmacol       Date:  2015-04-22       Impact factor: 4.436

2.  Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells.

Authors:  M Asano; T Nakajima; K Iwasawa; T Morita; F Nakamura; H Imuta; K Chisaki; N Yamada; M Omata; Y Okuda
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

3.  Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes.

Authors:  M Bähr; M Spelleken; M Bock; M von Holtey; R Kiehn; J Eckel
Journal:  Diabetologia       Date:  1996-07       Impact factor: 10.122

4.  Synthesis of new pyrazolyl-2, 4-thiazolidinediones as antibacterial and antifungal agents.

Authors:  Deepak K Aneja; Poonam Lohan; Sanjiv Arora; Chetan Sharma; Kamal R Aneja; Om Prakash
Journal:  Org Med Chem Lett       Date:  2011-11-08

Review 5.  Recent pharmacological developments on rhodanines and 2,4-thiazolidinediones.

Authors:  Ravinder Singh Bhatti; Sakshi Shah; Pawan Krishan; Jagir S Sandhu
Journal:  Int J Med Chem       Date:  2013-05-02

Review 6.  The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond.

Authors:  Pallavi R Devchand; Tianyun Liu; Russ B Altman; Garret A FitzGerald; Eric E Schadt
Journal:  Front Pharmacol       Date:  2018-10-04       Impact factor: 5.810

7.  Iminosugars Spiro-Linked with Morpholine-Fused 1,2,3-Triazole: Synthesis, Conformational Analysis, Glycosidase Inhibitory Activity, Antifungal Assay, and Docking Studies.

Authors:  Shrawan R Chavan; Kishor S Gavale; Ayesha Khan; Rakesh Joshi; Navanath Kumbhar; Debamitra Chakravarty; Dilip D Dhavale
Journal:  ACS Omega       Date:  2017-10-26

8.  Effect of troglitazone on radiation sensitivity in cervix cancer cells.

Authors:  Zhengzhe An; Xianguang Liu; Hyejin Song; Chihwan Choi; Won-Dong Kim; Jae-Ran Yu; Woo-Yoon Park
Journal:  Radiat Oncol J       Date:  2012-06-30

Review 9.  The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory.

Authors:  Mohammed I Khan; Anna A Sobocińska; Anna M Czarnecka; Magdalena Król; Bruno Botta; Cezary Szczylik
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

10.  Synthesis and Antimicrobial Activity of a New Series of Thiazolidine-2,4-diones Carboxamide and Amino Acid Derivatives.

Authors:  Rakia Abd Alhameed; Zainab Almarhoon; Sarah I Bukhari; Ayman El-Faham; Beatriz G de la Torre; Fernando Albericio
Journal:  Molecules       Date:  2019-12-27       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.